• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: Emerging talents in pharmacology: Drugs outcomes research and policies 2022.

作者信息

Linger Rachel M A, Fadare Joseph O, Shen Ye, Van Winkle Lon J

机构信息

Department of Biomedical Sciences, Rocky Vista University, Parker, CO, United States.

Department of Pharmacology and Therapeutics, College of Medicine, Ekiti State University, Ado-Ekiti, Nigeria.

出版信息

Front Pharmacol. 2023 Mar 2;14:1162703. doi: 10.3389/fphar.2023.1162703. eCollection 2023.

DOI:10.3389/fphar.2023.1162703
PMID:36937832
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10018119/
Abstract
摘要

相似文献

1
Editorial: Emerging talents in pharmacology: Drugs outcomes research and policies 2022.社论：药理学领域的新兴人才：2022年药物疗效研究与政策
Front Pharmacol. 2023 Mar 2;14:1162703. doi: 10.3389/fphar.2023.1162703. eCollection 2023.
2
Editorial: Emerging talents in pharmacology of anti-cancer drugs 2022.社论：2022年抗癌药物药理学领域的新兴人才
Front Pharmacol. 2023 Apr 19;14:1191321. doi: 10.3389/fphar.2023.1191321. eCollection 2023.
3
Editorial: Emerging talents in Frontiers in pharmacology: Gastrointestinal and hepatic pharmacology 2022.社论：《药理学前沿》2022年胃肠与肝脏药理学领域的新兴人才
Front Pharmacol. 2022 Oct 21;13:1055030. doi: 10.3389/fphar.2022.1055030. eCollection 2022.
4
Editorial: Emerging talents in pharmacology of ion channels and channelopathies 2022.社论：2022年离子通道药理学与通道病领域的新兴人才
Front Pharmacol. 2023 Apr 12;14:1191328. doi: 10.3389/fphar.2023.1191328. eCollection 2023.
5
Editorial: Emerging talents in frontiers in pharmacology: pharmacogenetics and pharmacogenomics 2022.社论：2022年药理学前沿领域的新兴人才：药物遗传学和药物基因组学
Front Pharmacol. 2023 Oct 27;14:1307602. doi: 10.3389/fphar.2023.1307602. eCollection 2023.
6
Editorial: Emerging talents in Frontiers in Pharmacology: Drug metabolism and transport 2022.社论：《药理学前沿：药物代谢与转运》2022年的后起之秀
Front Pharmacol. 2022 Dec 7;13:1083163. doi: 10.3389/fphar.2022.1083163. eCollection 2022.
7
Nursing student perceptions of pharmacology education and safe medication administration: A qualitative research study.护理专业学生对药理学教育和安全用药管理的认知：一项定性研究。
Nurse Educ Today. 2019 Mar;74:76-81. doi: 10.1016/j.nedt.2018.12.006. Epub 2018 Dec 22.
8
Editorial: Emerging talents in human neuroscience: Cognitive neuroscience 2022.社论：人类神经科学领域的新兴人才：2022年认知神经科学
Front Hum Neurosci. 2023 Mar 15;17:1171860. doi: 10.3389/fnhum.2023.1171860. eCollection 2023.
9
Emerging country pharmacology: a 10-year perspective from Naunyn-Schmiedeberg's Archives of Pharmacology.新兴国家药理学：来自《瑙尼恩-施米德贝格药理学文献》的十年展望
Naunyn Schmiedebergs Arch Pharmacol. 2011 Sep;384(3):217-9. doi: 10.1007/s00210-011-0659-1. Epub 2011 Jun 9.
10
Using the patient's medication history as a learning tool in clinical pharmacology instruction for dental students.将患者用药史作为牙科学临床药理学教学的学习工具。
J Dent Educ. 2012 Nov;76(11):1482-90.

本文引用的文献

1
Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.阿司匹林用于预防心血管疾病和结直肠癌：美国预防服务工作组的更新证据报告和系统评价。
JAMA. 2022 Apr 26;327(16):1585-1597. doi: 10.1001/jama.2022.3337.
2
Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement.阿司匹林用于预防心血管疾病：美国预防服务工作组推荐声明。
JAMA. 2022 Apr 26;327(16):1577-1584. doi: 10.1001/jama.2022.4983.
3
Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.基于真实世界临床证据评估西班牙 2 型糖尿病患者使用固定比例复方胰岛素德谷胰岛素/利拉鲁肽（IDegLira）的长期成本效益。
Diabetes Obes Metab. 2019 Jun;21(6):1349-1356. doi: 10.1111/dom.13660. Epub 2019 Mar 20.
4
Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system.在斯洛伐克医疗体系中，德谷门冬双胰岛素与基础-餐时胰岛素治疗2型糖尿病患者的成本效益分析。
Clinicoecon Outcomes Res. 2017 Dec 12;9:749-762. doi: 10.2147/CEOR.S143127. eCollection 2017.
5
Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.在美国，对德谷胰岛素利拉鲁肽与在基础胰岛素治疗基础上加用利拉鲁肽用于血糖控制不佳的2型糖尿病患者的长期成本效益评估。
J Med Econ. 2017 Jul;20(7):663-670. doi: 10.1080/13696998.2017.1301943. Epub 2017 Mar 15.
6
Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.德谷胰岛素利拉鲁肽（IDegLira）固定复方制剂治疗瑞典未控制的2型糖尿病的成本效益
Appl Health Econ Health Policy. 2017 Apr;15(2):237-248. doi: 10.1007/s40258-016-0301-y.
7
Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting.在英国，德谷胰岛素利拉鲁肽与其他基础胰岛素强化治疗方案相比，用于基础胰岛素治疗血糖控制不佳的2型糖尿病患者的成本效益分析。
Pharmacoeconomics. 2016 Sep;34(9):953-66. doi: 10.1007/s40273-016-0433-9.